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Abstract
Background
Plasmodium vivax has been recently discovered as a significant cause of malaria in Maurita-
nia, although very rare elsewhere in West Africa. It has not been known if this is a recently
introduced or locally remnant parasite population, nor whether the genetic structure reflects
epidemic or endemic transmission.
Methodology/Principal findings
To investigate the P. vivax population genetic structure in Mauritania and compare with pop-
ulations previously analysed elsewhere, multi-locus genotyping was undertaken on 100 clin-
ical isolates, using a genome-wide panel of 38 single nucleotide polymorphisms (SNPs),
plus seven SNPs in drug resistance genes. The Mauritanian P. vivax population is shown to
be genetically diverse and divergent from populations elsewhere, indicated consistently by
genetic distance matrix analysis, principal components analyses, and fixation indices. Only
one isolate had a genotype clearly indicating recent importation, from a southeast Asian
source. There was no linkage disequilibrium in the local parasite population, and only a
small number of infections appeared to be closely genetically related, indicating that there is
ongoing genetic recombination consistent with endemic transmission. The P. vivax diversity
in a remote mining town was similar to that in the capital Nouakchott, with no indication of
local substructure or of epidemic population structure. Drug resistance alleles were virtually
absent in Mauritania, in contrast with P. vivax in other areas of the world.
Conclusions/Significance
The molecular epidemiology indicates that there is long-standing endemic transmission that
will be very challenging to eliminate. The virtual absence of drug resistance alleles suggests
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that most infections have been untreated, and that this endemic infection has been more
neglected in comparison to P. vivax elsewhere.
Author summary
Plasmodium vivax is a widespread cause of malaria in Mauritania, in contrast to its rarity
elsewhere throughout West Africa. To investigate whether the parasite may be recently
introduced or epidemic, multi-locus genotyping was performed on 100 Mauritanian P.
vivaxmalaria cases. Analysis of a genome-wide panel of single nucleotide polymorphisms
showed the P. vivax population to be genetically diverse and divergent from populations
elsewhere, indicating that there has been long-standing endemic transmission. Almost all
infections appear to be locally acquired, with the exception of one that was presumably
imported with a genotype similar to infections seen in Southeast Asia. The Mauritanian P.
vivax population shows no linkage disequilibrium, and very few infections have closely
related genotypes, indicating ongoing recombination. The parasite showed no indication
of local substructure or epidemic population structure. Drug resistance alleles were virtu-
ally absent, suggesting that most infections have been untreated historically. The molecu-
lar epidemiology indicates that there has been long-standing endemic transmission of this
neglected parasite that requires special attention for control.
Introduction
On the edge of the Sahara in northwest Africa, Mauritania is endemic for malaria, with the
majority of cases normally attributed to Plasmodium falciparum [1]. Analysis of parasite DNA
from clinical samples indicates that most malaria in the Sahel zone in the south of the country
is caused by P. falciparum [2], whereas P. vivax predominates in the central and northern
regions of the country within the arid Saharan zone [2–4]. Routine laboratory-based diagnos-
tic testing is conducted in health centres where facilities allow, using either slide microscopy or
rapid diagnostic tests, although presumptive clinical diagnosis has also been commonly
applied. Chloroquine was first-line treatment for uncomplicated clinical malaria in Mauritania
until 2006, with sulphadoxine-pyrimethamine being only occasionally used, and since then
artemisinin combination therapy with artesunate-amodiaquine has been officially first-line
treatment for all uncomplicated malaria cases, while sulphadoxine-pyrimethamine is reserved
for intermittent preventive treatment during pregnancy [3].
There is evidence suggesting that P. vivax in humans emerged in Africa as a spill-over zoo-
nosis from a reservoir in great apes [5,6], but this parasite species is now rare in most of the
continent apart from the Horn of East Africa [7,8] and some analyses suggest historical emer-
gence from southeast Asia [9,10], so the origin and epidemiology in northwest Africa remains
obscure. It is vital to know whether P. vivax has emerged in Mauritania in the recent past, as
was assumed in the initial report of its presence in the country [11], or whether this is a long-
established endemic parasite whose presence has only been recognised recently.
Genotypic characterization can provide important information on the origins of parasite
populations and their relationships to those elsewhere, and can also illuminate local population
structure and variation in transmission [12], as well as the prevalence and spread of drug resis-
tance [13]. Here, we employed multi-locus single nucleotide polymorphism (SNP) analysis of
a genome-wide set of loci [14] to analyse P. vivax population genetic structure in patient sam-
ples from three areas in Mauritania where this species was noted to be the most common
PLOS NEGLECTED TROPICAL DISEASES Separate population of vivax malaria in Mauritania
PLOSNeglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008945 December 16, 2020 2 / 14
Funding: This study was primarily funded by the
UKMedical Research Council (MRC) Project Grant
G1100123 to DJC and HB. Parasite genotyping
was enabled by the SPOT-Malaria project through
the MalariaGEN consortium led by DPK with
funding from theWellcome Trust. RNP is
supported by theWellcome Trust, SA is supported
by the Bill and Melinda Gates Foundation, and a
Georgina Sweet Award for Women in Quantitative
Biomedical Science. The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
cause of malaria [2], and also analysed candidate drug resistance markers in the same samples.
In comparison with genotypic data on P. vivax populations in other countries, the P. vivax
population in Mauritania is distinct, and almost all of the infections appeared to have been
acquired within the country. The P. vivax population in Mauritania showed no evidence of
genetic sub-structure, and is apparently highly recombining, consistent with long-established
and ongoing endemicity. Controlling this infection requires characterization of the epidemiol-
ogy in areas that have had minimal attention previously, and a commitment to radical cure
will be important for regional elimination.
Methods
Ethics Statement
All samples were obtained with written informed consent from patients with malaria present-
ing for treatment, as well as guardians of any patients who were under 18 years of age. The
study was approved by ethics committees of the Ministry of Health of Mauritania and the Lon-
don School of Hygiene and Tropical Medicine (Ethics approval number 6043).
Plasmodium vivax clinical infection samples
P. vivax infections from patients presenting to local health centres and hospitals in different
parts of Mauritania in 2012 and 2013 were previously identified by slide microscopy [15] and
confirmed by species-specific PCR of genomic DNA from samples collected on filter paper [2].
All cases were local residents who did not report having travelled within the previous two
weeks, and who were invited to provide finger-prick blood samples which were collected on fil-
ter paper and air-dried prior to storage with desiccant in sealed polythene bags. All samples
were obtained with informed consent from patients, and guardians of patients who were under
18 years of age. After molecular confirmation of species, DNA from 100 isolates was analysed
successfully by multi-locus SNP genotyping. Most of these (N = 91) were from the capital city
Nouakchott, located on the Atlantic coast in the southern edge of the Sahara zone with low
annual rainfall (100–200 mm), and dependent on a supply of piped water from the Senegal
River basin in the south of the country. A smaller number of genotyped samples (N = 8) were
from Zouérat, an iron ore mining town in the extremely arid northern Sahara zone of the coun-
try (receiving less than 50 mm annual rainfall), all cases being local residents as the mining
operation is long-established and supports a developed urban area with a settled economy and
extended families. A single genotyped sample was from N’beika, a small oasis town in the
Sahara zone in the central part of the country (receiving 50–200 mm annual rainfall) (Fig 1). All
of the P. vivax cases in this study were from individuals with Duffy positive genotypes as deter-
mined by PCR analysis previously [2], reflecting that this parasite species is mainly seen in areas
of the country where most of the population are of the majority Maure ethnicity.
Multi-locus SNP genotyping
Genotyping was undertaken for a panel of 38 SNP loci from across the P. vivax genome
(including markers on all of the 14 chromosomes), representing 90% of the SNPs on a previ-
ously described array of putatively neutral markers [14] for which amplicon-based sequencing
assays were used in genotyping here (S1 Table). In addition, seven SNPs that have been associ-
ated with drug resistance elsewhere were genotyped, in the genes encoding dihydropteroate
synthase (dhps, codon polymorphisms A553G and A383G), dihydrofolate reductase (dhfr,
codon polymorphisms F57L/I, S58R, T61M and S117N/T), and the multidrug resistance 1
locus (mdr1, codon Y976F) [16]. Genotyping was performed using amplicon-based
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sequencing on the Illumina MiSeq platform at the Wellcome Sanger Institute, with reference
alleles based on the PvP01 P. vivax reference genome sequence [17]. Individual infection sam-
ples were considered valid for analysis if clear genotyping scores could be obtained for more
than half of the SNP loci, yielding a total of 100 infections for analysis (in most of these samples
complete data were obtained for all SNP loci as noted in the Results).
To compare P. vivax fromMauritania with parasite populations in other countries, the SNP
genotypes for these same loci were derived using VCFtools from previously published genome
sequence data from P. vivax clinical isolates collected in Ethiopia (2013, N = 24), Thailand
(2006–2013, N = 104), Papua Province in Indonesia (2011–2014, n = 111) [18–20], Mexico
(2000–2007, n = 20) [21], and Colombia (2012–2013, n = 31) [21].
Population genetic and statistical analysis
The population genetic structure analyses focused on the 38 putatively neutral SNPs from
throughout the P. vivax genome, while the seven drug resistance SNPs were analysed
Fig 1. Map showing the location of the sampling sites of 100 P. vivaxmalaria cases in Mauritania analysed by multi-locus genotyping in this study.Most cases
analysed were from the capital city (Nouakchott, N = 91), while eight were from a northern mining town (Zouérat), and one was from a central oasis town (N’beika).
The map of Africa to the right shows the location of Mauritania and surrounding countries in northwest Africa illustrated in the main map.
https://doi.org/10.1371/journal.pntd.0008945.g001
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separately. If mixed alleles at a particular SNP were detected in an infection sample, the major
one (with the highest read depth) was scored to contribute to the multi-locus genotype profile,
and if this was not clear the SNP call was recorded as missing. A pairwise measure of genetic
distance between infections (1-ps) considered the proportion of alleles shared (ps), and a Neigh-
bor-Joining tree of the distance matrix was generated using the ape package in R and iTOL soft-
ware [22,23]. Similarity of individual samples was also assessed using Principal Component
Analysis (PCA) using the ClustVis software (htps://biit.cs.ut.ee/clustvis). The degree of diver-
gence between Mauritania and other geographical populations was assessed using the fixation
index (FST), employing the Scikitallel package (https://github.com/cggh/scikit-allel) to deter-
mine Hudson’s FST estimator, and using an in-house R script to calculate Weir and Cocker-
ham’s FST as these different estimators focus on slightly different components of the allele
frequency spectra [24]. Within-population SNP diversity was assessed using the virtual hetero-
zygosity index (He), the mean of the pairwise differences at each marker between isolates within
a given population. A within-population multi-locus measure of statistical linkage disequilib-
rium (LD) among the SNP loci was provided by the Index of Association (ISA), calculated for
samples with complete multi-locus genotype data using LIAN version 3.7 software [25]. This
measure of LD was assessed by analysing all samples that included mixed infections, as well as
only in samples that had single genotype infections, and with unique multi-locus genotypes.
The single genotype infections were defined as those that yielded a Complexity of Infection of 1
using the COIL algorithm [26]. R software was used for statistical tests, including Pearson’s
Chi-squared test with Yates’ continuity correction for analysis of categorical variables.
Results
High-quality multi-locus SNP genotyping of Mauritanian P. vivax samples
Of the 100 Mauritanian P. vivax infection samples that had sufficient DNA for genotyping in
this study, 84 yielded complete SNP data for all loci (38 loci genome-wide plus seven SNPs in
drug resistance genes), and only six samples had>30% SNPs drop out. Twelve of the 100 infec-
tion samples contained multiple genotypes at any of the SNP loci, hence the haploid multi-locus
genotype could be resolved unequivocally for 88 infections, of which 80 had complete data for
all SNPs (all multi-locus genotypes for all individual samples are shown in S1 Datasheet).
Population genetic diversity of P. vivax in Mauritania and divergence from
other populations
Based on the array of 38 putatively neutral SNP markers from throughout the genome, there
was a high level of diversity in Mauritania, assessed by the virtual heterozygosity index of pair-
wise differences among all infections averaged across all SNPs (He = 0.31). Analysis of the pair-
wise genetic differences revealed that almost all infections were different from each other. The
samples from Zouérat and N’beika were distributed in the same overall range of diversity
amongst those from Nouakchott, indicating no genetically separated parasite subpopulations
within the country. With exception of three infections from Nouakchott, the Mauritanian
samples formed a distinct geographical group, with slightly closer relatedness to previous sam-
ples from Ethiopia as well as Central and South America than to most samples from Southeast
Asia (Fig 2 and S1 Fig). Of the three outlier infections, two were only slightly outside the
grouping of most Mauritanian samples, but one (isolate NKT136 from Nouakchott) was
closely related to parasites previously sampled from Southeast Asia.
Among all of the Mauritanian samples, only three pairs of infections had identical multi-
locus genotypes (Fig 2). These were not epidemiologically linked, NKT144 and TY004 having
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been sampled 123 days apart in Nouakchott, TEY46 and TY048 sampled 312 days apart in
Nouakchott, and TY047 and ZL019 respectively sampled 210 days apart in Nouakchott and
Zouérat. There was no significant multi-locus linkage disequilibrium in the total population
sample fromMauritania (IA
S = 0.002, P> 0.05), or separately within Nouakchott (IA
S = 0.002,
P> 0.05) or Zouérat (IA
S = -0.012, P> 0.05). Multi-locus LD remained low in Mauritania
when analysis was restricted to single genotype infections (IA
S = 0.0004, P> 0.05) and infec-
tions with unique multi-locus genotypes (IA
S = 0.002, P> 0.05). This is consistent with
Fig 2. Neighbor-Joining tree illustrating the genetic relatedness among P. vivax infections in Mauritania in comparison with previous samples from other
countries, based on multi-locus genotypes based on a distance matrix using the genome-wide panel of 38 SNPs genotyped in this study.Data are presented on all
samples fromMauritania (n = 100) and a random selection of 10 samples from each of Ethiopia, Thailand, Indonesia, Mexico and Colombia. For visual clarity, a rooted
tree is shown using an arbitrarily selected isolate from Indonesia (PJ0316-C) as the ‘root’ (note that this is not a phylogenetic tree but a genetic distance dendrogram of a
recombining species, and an unrooted tree has similar topology shown in S1 Fig). Within Mauritania, isolates from the mining town Zouérat and the oasis town N’beika
were not genetically separated from samples from the capital city Nouakchott. Mauritanian isolates are diverse but comprise a population distinct from those in the
other countries, except for two isolates that are similarly divergent as those from Ethiopia and one isolate (NKT136), showing closer genetic relatedness to the Asian
parasites.
https://doi.org/10.1371/journal.pntd.0008945.g002
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established endemicity and ongoing genetic recombination in the local P. vivax population,
without any evidence of clonal or epidemic population structure which is seen elsewhere when
local transmission is unstable (S2 Table).
Principal Component Analysis confirmed that almost all of the Mauritanian P. vivax infec-
tion samples clustered separately from those previously sampled in other countries, although
they were more closely related to those from Ethiopia than from other continents (Fig 3). Con-
sistent with the Neighbor-Joining analysis, it showed that one infection sample (NKT136 from
Nouakchott) was genetically similar to parasites from Asia. Further Principal Component
Analyses comparing Mauritania with each of the other countries separately, confirmed that all
P. vivax samples fromMauritania clustered separately from all others (except isolate NKT136
which consistently clustered with Asian P. vivax samples) (S2 Fig).
The genetic differentiation between the Mauritanian P. vivax population and those from
other countries was also estimated using the inter-population fixation index FST based on allele
frequencies, revealing a high level of divergence from Ethiopia (FST = 0.22 using Hudson’s
Fig 3. Principal Component Analysis (PCA) plot illustrating genetic relatedness among P. vivax infections in Mauritania compared with previous data from
other endemic countries [18–20]. The first two principal components are shown, illustrating that the parasite population in Mauritania is distinct from the Southeast
Asian and Central and South American populations, and has only a minor degree of overlap with samples from Ethiopia. In agreement with Neighbour-Joining analysis
of genetic distance (shown in Fig 2), the single isolate NKT136 from Nouakchott clustered with parasites from Southeast Asia. Further Principal Component Analysis of
the Mauritanian data with each of the other populations separately confirm the population distinctness (with the exception of isolate NKT136), and also show that
isolates from different sampled areas of Mauritania are not genetically separated (S2 Fig).
https://doi.org/10.1371/journal.pntd.0008945.g003
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estimator) and even higher divergence from populations previously sampled in other conti-
nents (S3 Table, also shows FST values using Weir and Cockerham’s estimator with slightly
lower values but the same trend).
Extremely low frequency of drug resistance alleles in P. vivax in Mauritania
The proportion of infections containing drug resistance-associated SNP alleles was investi-
gated, and shown to be exceptionally low compared with data from other geographical popula-
tions of P. vivax (Table 1). Notably, there were no antifolate resistance-associated alleles at
codons 57, 58 and 61 of the dihydrofolate reductase (dhfr) gene in Mauritania (Table 1). Alleles
at codon 58 were common in most other P. vivax populations including Ethiopia (P< 1 x
10−15 for each comparison with Mauritania), and at codons 57 and 61 were very common in
the Asian populations (P< 1 x 10−15 for each comparison with Mauritania). One infection in
Mauritania had a resistance-associated allele at codon 117 of dhfr (S117N), but this was infec-
tion sample NKT136 that was shown by the multi-locus analysis of neutral SNPs to be geneti-
cally similar to Asian parasites, so the occurrence of this allele is likely to reflect an exceptional
case of imported malaria (individuals who had travelled within the two weeks prior to diagno-
sis were not included in the study but earlier travel was not recorded).
At the dihydropteroate synthase (dhps) gene, there were no resistance-associated alleles in
Mauritania at codon 553 (Table 1), and a resistance-associated allele at codon 383 was only
detected in two infections, one of which was NKT136 that has a genotypic profile of Asian P.
vivax as noted above. The virtual absence of resistance-associated dhps alleles in Mauritania
contrasts with other populations, including Ethiopia where such alleles are of moderately low
frequency (P = 0.021), and populations in other continents where they are very common
(P< 1 x 10−5 for each comparison, except for codon 383 in Mexico) (Table 1). In the multi-
drug resistance gene (mdr1), the Y976F variant which has been loosely associated with chloro-
quine resistance elsewhere [27] was detected in 14% of infections in Mauritania (Table 1).
Discussion
Although P. vivax has only been recognised as a significant cause of malaria in Mauritania
recently, this study indicates that the parasite has been long-established in northwest Africa,
and that it is a genetically distinctive sub-population compared with parasites from other areas
of the world. A genome-wide panel of 38 SNP loci revealed a high level of P. vivax genetic
diversity in Mauritania, and no evidence of linkage disequilibrium or population genetic sub-
structure within the country. The P. vivax population in Mauritania is clearly genetically
Table 1. Low frequency of SNP variants in P. vivax drug resistance genes in Mauritania compared with other endemic populations.
Percentage of isolates containing resistance-associated variants (with numbers in brackets) in:
Gene Codon Allele Mauritania Ethiopia Thailand Indonesia Mexico Colombia
dhfr F57L/I 0 (0/89) 0 (0/24) 91 (88/97) 82 (77/94) 0 (0/20) 0 (0/31)
S58R 0 (0/87) 94 (17/18) 100 (104/104) 99 (104/105) 0 (0/20) 97 (30/31)
T61M 0 (0/90) 0 (0/24) 91 (90/99) 82 (77/94) 0 (0/20) 0 (0/31)
S117N/T 1 (1/98) 100 (24/24) 100 (102/102) 99 (93/94) 0 (0/20) 97 (30/31)
dhps A553G 0 (0/99) 0 (0/24) 98 (98/100) 16 (16/97) 100 (20/20) 100 (31/31)
A383G 2 (2/100) 17 (4/24) 100 (104/104) 97 (106/109) 0 (0/20) 84 (26/31)
mdr1 Y976F 14 (14/100) 32 (6/19) 13 (14/104) 100 (111/111) 0 (0/19) 3 (1/29)
Data for Mauritania are from the current study, compared alongside previously published data from Ethiopia [19], Thailand [18,20], Indonesia [18], Mexico [21] and
Colombia [21].
https://doi.org/10.1371/journal.pntd.0008945.t001
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divergent from other geographical populations of the parasite, including Ethiopia which is the
source of most samples from the African continent that have been analysed by sequencing
[19,28,29]. A recent survey of 14 microsatellite loci has also indicated the distinctiveness of P.
vivax samples fromMauritania compared to most other sampled populations in Africa, Asia
or the Americas [10], further supporting the evidence for an established focus of endemicity.
It is notable that there is no evidence for a clonal or epidemic population genetic structure
of P. vivax in Mauritania, whereas such structure has been seen in populations close to elimi-
nation, such as described in Malaysia [30] and parts of Central and South America [21]. The
areas where P. vivax infections were sampled in Mauritania experience extremely low annual
rainfall, within only a few months of the year at most and sometimes none, and this would
clearly limit opportunities for transmission by mosquitoes. The other endemic species P. fal-
ciparum has been shown to occasionally have an epidemic population structure at a minority
of sites sampled further south in the country where rainfall is not quite so low [31]. As P. vivax
showed no evidence of a clonal or epidemic structure in extremely dry areas studied here, it is
likely that many infections persist for multiple years due to latency of liver-stage parasites,
occasional relapses allowing ongoing transmission to occur when conditions allow. For future
control and to aim towards eventual elimination, radical cure of P. vivax infections using
either primaquine or tafenoquine will be needed, which would require screening for glucose
6-phosphate dehydrogenase deficiency of patients to reduce the risk of haemolytic anaemia as
a side effect [32].
This northwest African P. vivax population has probably been present since pre-history,
and may have previously been part of a wider geographical population. To the north, P. vivax
was eliminated fromMorocco in 2010, and used to be present in neighbouring Algeria where
it is now almost eliminated [1,33]. This may even be part of the same parasite population that
was endemic in Europe until malaria was eliminated in the mid-twentieth century. Sequencing
of archival P. vivax from Europe could be performed, as illustrated by analysis of a single speci-
men so far [34], and once there are data from a range of other samples their relatedness to
sequences from parasites in Mauritania should be determined. It is an ongoing priority to
increase the amount of P. vivax whole-genome sequence data from infections in Mauritania
and other countries where the epidemiology and population history is unclear [35].
To the east and south of Mauritania, a small number of P. vivax infections have been docu-
mented in Mali and Senegal respectively [36–38], and it is now considered that this species
may occur at low densities more widely in Africa than previously assumed [39,40]. It will be
important to genotype P. vivax from other African countries to ascertain if there are any other
endemic populations, and any connectivity among them, or if infections elsewhere reflect spo-
radic introductions. The substantial genetic divergence we show between P. vivax in Maurita-
nia and Ethiopia indicates that there is little gene flow between these two main endemic foci in
Africa, consistent with the parasite having only a very sparse and discontinuous endemic dis-
tribution elsewhere on the continent.
Analysis of dhfr and dhps genotypes revealed a virtual absence of antifolate resistance-asso-
ciated variants in P. vivax in Mauritania. Consistent with this, drug resistance genotyping of P.
vivax samples previously taken from Nouakchott in 2007–9 and 2013–16 also showed no resis-
tance-associated alleles in dhps [41,42]. However, the same studies reported between 10 and
20% of infections to have double mutant alleles of dhfr (combinations of variants at codons 58,
61 and 117) [41,42], in contrast to results here that showed an absence of resistance-associated
alleles at these codons (except for a single variant at codon 117 in infection sample NKT136
that had an overall genotype similar to Asian parasites). Antimalarial antifolate use in Maurita-
nia is now limited to intermittent preventative treatment of pregnant women with sulphadox-
ine-pyrimethamine [41], although antifolates were previously used for therapy along with
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chloroquine. Comparing this and previous studies, the frequency of themdr1 976F allele in
Mauritania varied from 28% in 2007–9 to 14% in 2012–13, and 4% in 2013–16 [41,42], which
may reflect a decline due to fitness cost after chloroquine use officially stopped following intro-
duction of Artemisinin Combination Therapy in 2006, although the allele is not a marker of
chloroquine resistance and is at most a minor modulator [16]. Clinical evidence indicates that
most local P. vivax infections are sensitive to chloroquine treatment [43].
In line with political and public health aspirations, Mauritania is aiming to eliminate
malaria by 2030, but for this to be attainable a much deeper understanding of P. vivax in the
region will be essential, as this species is particularly difficult to eliminate [1,44,45]. The dis-
tinct genetic profile of Mauritanian P. vivax compared with parasites elsewhere has important
implications. It is highly likely that this population has locally adapted, to maintain parasites in
the extreme conditions of the Sahara where opportunities for mosquito vector transmission
must be exceedingly rare. Further epidemiological monitoring, clinical studies and genomic
analyses of parasites from this unusual population will be necessary to understand this highly
important parasite species that has been so long overlooked in Africa.
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S1 Fig. Unrooted Neighbor-Joining tree illustrating the genetic relatedness among P. vivax
infections in Mauritania and previous samples from other countries, as described in the
Methods and Results, based on a distance matrix of multi-locus genotypes using the panel
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Colombia as cited in the Methods and Results). The outlier isolate NKT136 which shows
genetic similarity to those from Southeast Asia is circled.
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Algérien. Bull Soc Pathol Exot. 2009; 102:185–92. PMID: 19739417.
34. van Dorp L, Gelabert P, Rieux A, de Manuel M, de-Dios T, Gopalakrishnan S, et al. Plasmodium vivax
malaria viewed through the lens of an eradicated European strain. Mol Biol Evol. 2019. Epub 2019/11/
08. https://doi.org/10.1093/molbev/msz264 PMID: 31697387.
35. Daron J, Boissiere A, Boundenga L, Ngoubangoye B, Houze S, Arnathau C, et al. Population genomic
evidence of a Southeast Asian origin of Plasmodium vivax. BioRxiv. 2020:doi: https://doi.org/10.1101/
2020.04.29.067439.
36. Niangaly A, Karthigayan G, AmedO, Coulibaly D, Sa JM, AdamsM, et al. Plasmodium vivax Infections
over 3 Years in Duffy Blood Group Negative Malians in Bandiagara, Mali. Am J Trop Med Hyg. 2017;
97:744–52. https://doi.org/10.4269/ajtmh.17-0254 PMID: 28749772.
37. NiangM, Thiam LG, Sow A, Loucoubar C, Bob NS, Diop F, et al. A molecular survey of acute febrile ill-
nesses reveals Plasmodium vivax infections in Kedougou, southeastern Senegal. Malar J. 2015;
14:281. https://doi.org/10.1186/s12936-015-0808-y PMID: 26186936.
38. NiangM, Diop F, Niang O, Sadio BD, Sow A, Faye O, et al. Unexpected high circulation of Plasmodium
vivax in asymptomatic children from Kedougou, southeastern Senegal. Malar J. 2017; 16:497. https://
doi.org/10.1186/s12936-017-2146-8 PMID: 29284488.
39. Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global Epidemiology of Plas-
modium vivax. Am J Trop Med Hyg. 2016; 95:15–34. https://doi.org/10.4269/ajtmh.16-0141 PMID:
27402513.
40. Zimmerman PA. Plasmodium vivax infection in Duffy-negative people in Africa. Am J Trop Med Hyg.
2017; 97:636–8. https://doi.org/10.4269/ajtmh.17-0461 PMID: 28990906.
41. Mint Deida J, Ould Khalef Y, Mint Semane E, Ould Ahmedou SalemMS, Bogreau H, Basco L, et al.
Assessment of drug resistance associated genetic diversity in Mauritanian isolates of Plasmodium
vivax reveals limited polymorphism. Malar J. 2018; 17:416. https://doi.org/10.1186/s12936-018-2548-2
PMID: 30409138.
42. Mint Lekweiry K, Ould Mohamed Salem Boukhary A, Gaillard T, Wurtz N, Bogreau H, Hafid JE, et al.
Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in
Nouakchott, Mauritania. J Antimicrob Chemother. 2012; 67:367–74. https://doi.org/10.1093/jac/dkr464
PMID: 22086859.
43. Ould Ahmedou SalemMS, Mohamed Lemine YO, Deida JM, Lemrabott MA, Ouldabdallahi M, Ba MD,
et al. Efficacy of chloroquine for the treatment of Plasmodium vivax in the Saharan zone in Mauritania.
Malar J. 2015; 14:39. https://doi.org/10.1186/s12936-015-0563-0 PMID: 25626475.
PLOS NEGLECTED TROPICAL DISEASES Separate population of vivax malaria in Mauritania
PLOSNeglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008945 December 16, 2020 13 / 14
44. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of
malaria elimination: new strategies for new challenges. Lancet. 2013; 382:900–11. https://doi.org/10.
1016/S0140-6736(13)60310-4 PMID: 23594387.
45. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the era of the shrinking
P. falciparummap. Trends Parasitol. 2020; 36:560–70. Epub 2020/05/15. https://doi.org/10.1016/j.pt.
2020.03.009 PMID: 32407682.
PLOS NEGLECTED TROPICAL DISEASES Separate population of vivax malaria in Mauritania
PLOSNeglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008945 December 16, 2020 14 / 14
